LLY · News · 20260921N
Competition and market share - weight-loss
ELI LILLY & Co · 2026-09-21 · Importance 17 · Surprise 24 · In source text
Novo Nordisk projected peer-average growth through 2030 and highlighted a 2032 patent cliff for semaglutide, the active ingredient in Wegovy and Ozempic. The disclosure increased investor concerns about competition in the weight-loss market, including pressure from next-generation obesity treatments such as Viking Therapeutics’ candidates. Eli Lilly was identified as a direct competitor, although the report gave no quantified effect on Lilly revenue or market share.
Key facts
- The facility will be instrumental in manufacturing orforglipron, Lilly’s oral GLP-1 receptor agonist, which the company plans to submit for regulatory approval for obesity by year-end. source
- Following Novo Nordisk's capital markets day and comments on competition, Eli Lilly, a direct competitor, saw only a slight dip in its stock. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The facility will be instrumental in manufacturing orforglipron, Lilly’s oral GLP-1 receptor agonist, which the company plans to submit… |